Complex Isopathic Drug Development for Neuroprotection
用于神经保护的复杂同向药物开发
基本信息
- 批准号:6431273
- 负责人:
- 金额:$ 16.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-02-15 至 2004-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Stroke is the third leading cause of death
in the United States and the leading cause of disability. Diseases of
neurodegeneration and brain damage from non-missile head trauma account for
nearly 500,000 hospital admissions in the U.S. annually. Although the etiology
may differ, the same anatomic and physiologic substrates are involved in these
conditions, including ischemia and hypoxic injury and the release of excitatory
amino acids, especially glutamate from diseased or damaged cells. We have been
using in vitro and in vivo models of experimental ischemia and cellular models
of glutamate toxicity to examine these mechanisms of neuronal injury, and to
target early intervention treatment strategies for neurodegeneration.
One promising strategy that has not been explored is the use of low doses of
chemicals to enhance cell tolerance and recovery. High doses of toxic chemicals
will inhibit and kill biological systems, while low doses frequently stimulate
those systems. Stimulation of cell function by exposure to low doses of
chemicals can often mitigate the adverse effects produced by high doses. This
phenomenon has been extensively studied in the area of toxicology called
"hormesis" and is the theoretical basis for the observed effects in some types
of homeopathy (specifically isopathy). While paradoxical dose effects have been
demonstrated across multiple cell types and phyla they have not yet been
examined in neurodegeneration. In preliminary research we have demonstrated
that protective effects occur in neuronal cells exposed to low and ultra-low
doses of glutamate and NMDA and that certain doses of glutamate/potassium
combinations protect against stroke in vivo.
The objective of this project is to use neuronal culture systems to identify
the optimal protective doses and of four neurotoxins that work by different
mechanisms - a glutamate/potassium preparation, NMDA, cycloheximide,
MPPepsilon, a combination of these. We will also begin preliminary examination
of selected mechanisms of the optimal protective combination and dose. This
project will, for the first time, have produced a systematic approach for use
of protective hormesis and will lay the foundation for the scientific
development of homeopathic and isopathic drugs in neurodegeneration and brain
injury.
描述(由申请人提供):中风是第三大死亡原因
是导致残疾的主要原因。疾病
非导弹头部创伤造成的神经变性和脑损伤
美国每年有近50万人入院。虽然病因
可能有所不同,但在这些过程中涉及相同的解剖学和生理学基质。
条件,包括缺血和缺氧损伤以及兴奋性神经递质的释放。
氨基酸,特别是来自患病或受损细胞的谷氨酸。我们一直
使用实验性局部缺血的体外和体内模型和细胞模型
谷氨酸毒性的研究,以检查神经元损伤的这些机制,并
针对神经退行性疾病的早期干预治疗策略。
一种尚未探索的有希望的策略是使用低剂量的
化学物质,以提高细胞的耐受性和恢复。高剂量的有毒化学物质
会抑制和杀死生物系统,而低剂量经常刺激
这些系统。通过暴露于低剂量的
化学品往往可以减轻高剂量产生的不利影响。这
这种现象在毒理学领域得到了广泛的研究,
“兴奋效应”,是在某些类型的观察效果的理论基础
顺势疗法(homeopathy)。虽然矛盾的剂量效应一直是
在多种细胞类型和门中证明了它们尚未被
在神经退行性变中检查。在初步研究中,我们已经证明,
保护作用发生在暴露于低浓度和超低浓度的
一定剂量的谷氨酸盐和NMDA以及一定剂量的谷氨酸盐/钾
组合在体内防止中风。
本项目的目的是利用神经元培养系统,
最佳保护剂量和四种神经毒素,
机制-谷氨酸/钾制剂,NMDA,放线菌酮,
MPPeppeptide,这些的组合。我们也将开始初步审查
最佳保护组合和剂量的选定机制。这
该项目将首次产生一种系统的方法,
保护性兴奋效应,并将为科学的
神经变性和脑中顺势疗法和等顺势疗法药物的发展
损伤
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WAYNE B JONAS其他文献
WAYNE B JONAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WAYNE B JONAS', 18)}}的其他基金
Complex Isopathic Drug Development for Neuroprotection
用于神经保护的复杂同向药物开发
- 批准号:
6621275 - 财政年份:2002
- 资助金额:
$ 16.01万 - 项目类别:
NEUROPROTECTION WITH GLUTAMATE AND ARNICA MONTANA
谷氨酸和山金车蒙大拿的神经保护
- 批准号:
6083988 - 财政年份:2000
- 资助金额:
$ 16.01万 - 项目类别:
相似国自然基金
固本祛湿化瘀方调控银屑病角质细胞与初始T细胞Aspartate交互的机制研究
- 批准号:82305246
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Balancing redox homeostasis and the metabolic network through metabolite compartmentalisation: SLC25A13, aspartate, and the mitochondrion
通过代谢物区室平衡氧化还原稳态和代谢网络:SLC25A13、天冬氨酸和线粒体
- 批准号:
BB/Y002865/1 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
Research Grant
Aspartate beta-hydroxylase and DNA damage in chronic liver diseases
慢性肝病中的天冬氨酸 β-羟化酶和 DNA 损伤
- 批准号:
10667881 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
Regulation of brown fat fuel utilization by the malate-aspartate shuttle
苹果酸-天冬氨酸穿梭对棕色脂肪燃料利用的调节
- 批准号:
10712090 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
The Malate-Aspartate shuttle links dietary fatty acids to inflammatory responses in dendritic cells
苹果酸-天冬氨酸穿梭将膳食脂肪酸与树突状细胞的炎症反应联系起来
- 批准号:
10772912 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
L-Aspartate signalling in the brain
大脑中的 L-天冬氨酸信号传导
- 批准号:
MR/W028964/1 - 财政年份:2022
- 资助金额:
$ 16.01万 - 项目类别:
Research Grant
The Malate-Aspartate shuttle links dietary fatty acids to inflammatory responses in dendritic cells
苹果酸-天冬氨酸穿梭将膳食脂肪酸与树突状细胞的炎症反应联系起来
- 批准号:
10528235 - 财政年份:2022
- 资助金额:
$ 16.01万 - 项目类别:
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy
操纵 N-乙酰基-L-天冬氨酸转运来治疗 Canavan 脑白质营养不良
- 批准号:
10406711 - 财政年份:2022
- 资助金额:
$ 16.01万 - 项目类别:
Manipulating N-acetyl-L-aspartate transport to treat Canavan leukodystrophy
操纵 N-乙酰基-L-天冬氨酸转运来治疗 Canavan 脑白质营养不良
- 批准号:
10554428 - 财政年份:2022
- 资助金额:
$ 16.01万 - 项目类别:
Role of altered endoplasmic reticulum calcium regulation and the N-methyl-D-aspartate (NMDA) receptor signaling in cortico-striatal synaptic dysfunction: Opportunities for therapy in prodromal Huntington disease
改变的内质网钙调节和 N-甲基-D-天冬氨酸 (NMDA) 受体信号在皮质纹状体突触功能障碍中的作用:前驱期亨廷顿病的治疗机会
- 批准号:
443591 - 财政年份:2021
- 资助金额:
$ 16.01万 - 项目类别:
Operating Grants
A Phase-2b, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-N-methyl-D-aspartate receptor (NMDAR) Encephalitis and Assess Markers of Disease
一项 2b 期、双盲、随机对照试验,旨在评估 Inebilizumab 在抗 N-甲基-D-天冬氨酸受体 (NMDAR) 脑炎中的活性和安全性并评估疾病标志物
- 批准号:
10185824 - 财政年份:2021
- 资助金额:
$ 16.01万 - 项目类别: